Mitsubishi Tanabe Pharma America, Inc. (MTPA) today announced five presentations at the 2024 Neuromuscular Study Group (NMSG) Annual Scientific Meeting being held in Tarrytown, N.Y., September 20-22.

Edaravone is under clinical development by Suzhou Auzone Biological Technology and currently in Phase I for Amyotrophic Lateral Sclerosis. According to GlobalData, Phase I drugs for Amyotrophic ...

Simcere Pharmaceuticals Group Ltd. (2096.HK) announced that Sanbexin Sublingual Tablets (Edaravone and Dexborneol sublingual ...

A simple blood test has been shown to be 98% accurate at distinguishing between patients with ALS and those without the ...

the approved on/off dosing regimen of oral edaravone in patients with ALS over 48 weeks. In addition, full results from the RADICAVA ORS Phase 3 open-label safety extension study (MT-1186-A03 ...

"For patients in the later stages of the disease, currently available treatments primarily involve life-sustaining measures, ...

"The evidence suggests that AMX0035 extends life, and it is clear that oral edaravone is far less burdensome than its infused preparation, but prices need to be greatly reduced to align with ...

Laxatives can be abused. People can overuse laxatives, leading to diarrhea as well as fluid and electrolyte abnormalities.

Motor neuron diseases are a group of progressive and ultimately fatal neurodegenerative disorders of the motor system, ...

(2096.HK) announced that Sanbexin Sublingual Tablets (Edaravone and Dexborneol sublingual tablets), an innovative drug for stroke, has been granted the Breakthrough Therapy designation by the U.S ...

Such treatments include drugs such as riluzole and edaravone. Related: Some people recover from ALS — now, we might know why ALS is a neurodegenerative disorder that affects the neurons in the ...